Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

By N. Labiris, M. Dolovich. British Journal of Clinical Pharmacology, 2003

1,169 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems (2018, background): “, liposomes and nanoliposomes) as a pulmonary drug delivery system also stems from the fact that phospholipids are naturally-occurring components of lung surfactant and, therefore, should not pose a toxicological risk to this organ [28,29].”
Organ-on-a-Chip Platforms for Studying Drug Delivery Systems (2014, neutral): “The alveoli themselves offer a thinmucosal barrier (200–800 nm) with low enzymatic action, vast absorptive surface area (100 m(2)) and rapid access to the bloodstream while avoiding invasive procedures [104].”